98% of patients who received GLIVEC following resection of primary KIT+ GIST achieved recurrence-free survival at 1 year1

GLIVEC reduced the risk of recurrence by 88%1*

GLIVEC significantly improved recurrence-free survival (RFS)1
  • The trial examined tumour sizes ranging from 3 cm to ≥10 cm1
  • The significant difference was similar across all tumour size categories1

Adjuvant treatment post resection significantly improves clinical outcomes1,2

  • While on treatment, only 1 recurrence event was observed, compared with 41 events on placebo1
  • Discuss with patients their individual risk tolerance prior to making a treatment decision
    An 8.5% risk of tumour recurrence may be acceptable for one patient but may be too high for another
*Relative risk reduction.

References: 1. DeMatteo RP, Ballman KV, Antonescu CR, et al; for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104. 2. Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2016.